The earnings call was largely positive, with strong revenue growth driven by both Vafseo and Auryxia, significant advancements in clinical trials, and an overall solid financial position. While there were some challenges with adherence rates and potential future competition for Auryxia, the positive aspects and future prospects significantly outweighed the negative points.

Company Guidance

During the second quarter of 2025, Akebia reported significant progress in the launch of Vafseo vadadustat, generating over $13 million in revenue, which marked a 55% increase from the first quarter. The company expanded patient access from 40,000 to 75,000 dialysis patients by securing prescribing access with midsized providers DCI and IRC, and projected further access to 275,000 patients with DaVita's upcoming operational pilot starting mid-August. This expansion aims to elevate Vafseo to a standard of care for treating anemia due to chronic kidney disease (CKD). Akebia also achieved over $60 million in total net product revenue, the highest in its history, driven by both Vafseo and Auryxia sales, with Auryxia alone bringing in $47.2 million. The company is focused on enhancing the environment for Vafseo post-TDAPA with ongoing trials like VOICE and VOCAL, and is planning to initiate the VALOR trial for nondialysis CKD patients by the year's end. With a strong cash position of $137.3 million, Akebia is well-positioned to advance its strategic goals.

Strong Revenue Growth

The company reported $62.5 million in total revenues for Q2 2025, up from $43.6 million in Q2 2024, marking an increase of $18.9 million. Net product revenues increased to $60.5 million from $41.2 million in the previous year.

Successful Launch of Vafseo

Vafseo generated over $13 million in revenue in Q2 2025, a 55% increase over Q1 2025. Prescribing access is expected to increase significantly, with access to over 275,000 dialysis patients anticipated in Q4 2025.

Auryxia Sales Growth

Auryxia sales increased to $47.2 million in Q2 2025 from $41.2 million in Q2 2024, despite losing IP exclusivity in March.

Positive Financial Position

The company ended Q2 2025 with $137.3 million in cash and cash equivalents and reported a net income of $247,000 compared to a net loss of $8.6 million in Q2 2024.

Expansion of Patient Access

The company reported that DaVita, a major dialysis provider, is expected to significantly increase patient access to Vafseo, with an operational pilot to conclude in Q4 2025.

Progress in Clinical Trials

The VOICE trial was fully enrolled with over 2,100 patients, and the VOCAL study in 18 DaVita dialysis facilities was initiated.

Akebia Therapeutics (AKBA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AKBA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.03 / -	-0.1	―	―	―
Aug 07, 2025	2025 (Q2)	-0.01 / 0.00	-0.04	―	―
May 08, 2025	2025 (Q1)	-0.04 / 0.03	-0.09	133.33% (+0.12)	―
Mar 13, 2025	2024 (Q4)	-0.08 / -0.10	0	―	―
Nov 07, 2024	2024 (Q3)	-0.06 / -0.10	-0.08	-25.00% (-0.02)	―
Aug 08, 2024	2024 (Q2)	-0.07 / -0.04	-0.06	33.33% (+0.02)	―
May 09, 2024	2024 (Q1)	-0.07 / -0.09	-0.14	35.71% (+0.05)	―
Mar 14, 2024	2023 (Q4)	-0.04 / 0.00	-0.04	―	―	―
Nov 08, 2023	2023 (Q3)	-0.09 / -0.08	-0.28	71.43% (+0.20)	―
Aug 25, 2023	2023 (Q2)	-0.03 / -0.06	0.15	-140.00% (-0.21)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AKBA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$3.78	$3.01	-20.37%
May 08, 2025	$2.46	$2.62	+6.50%
Mar 13, 2025	$1.93	$1.69	-12.44%
Nov 07, 2024	$2.00	$1.86	-7.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Akebia Therapeutics (AKBA) report earnings?

Akebia Therapeutics (AKBA) is schdueled to report earning on Nov 06, 2025, After Close (Confirmed).

What is Akebia Therapeutics (AKBA) earnings time?

Akebia Therapeutics (AKBA) earnings time is at Nov 06, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is AKBA EPS forecast?

AKBA EPS forecast for the fiscal quarter 2025 (Q3) is -0.03.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing